Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
← catalyst calendarNCT06415175 · readout in 42 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
143actual
Sites
15
Country
Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-14 | actual | When the study began enrolling |
| Primary completion | 2026-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-23 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Intervention
- Drug: Dupilumab
Primary outcomes
what the primary-completion date above is the date OFDemographic characteristic of pediatric patients initiating treatment with dupilumab for Severe AD: Age
measured At baseline
Demographic characteristic of pediatric patients initiating treatment with dupilumab for Severe AD: Gender
measured At baseline
Characteristic of pediatric patients initiating treatment with dupilumab for Severe AD:Body mass index (BMI)
measured At baseline
Medical history characteristics of pediatric patients initiating treatment with dupilumab for Severe AD
measured At baseline
Medical history of atopic comorbidities
measured At baseline
Medical history of non-atopic diseases
measured At baseline
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed